CLPBY
Get informed when a big investor buys or sells
+ FollowFebruary 6, 2026 - AI Summary
Overvalued by 28.4% based on the discounted cash flow analysis.
| Market cap | $13.50 Billion |
|---|---|
| Enterprise Value | $36.68 Billion |
| Dividend Yield | $0.36 (6.01%) |
| Earnings per Share | $1.52 |
| Beta | 0.52 |
| Outstanding Shares | 2,253,667,960 |
| P/E Ratio | 40.97 |
|---|---|
| PEG | -19.68 |
| Price to Sales | 0.67 |
| Price to Book Ratio | 1.2 |
| Enterprise Value to Revenue | 1.65 |
| Enterprise Value to EBIT | 6.23 |
| Enterprise Value to Net Income | 27 |
| Total Debt to Enterprise | 0.66 |
| Debt to Equity | 1.89 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
No data
This committee controls taxation, trade, and entitlement spending (e.g., Medicare/Medicaid). Its decisions on corporate tax policy directly impact profitability, and its influence on Medicare/Medicaid reimbursement rates significantly affects revenue streams for medical device manufacturers.
This committee directly allocates discretionary federal spending. Its subcommittees determine the precise funding for healthcare programs, agencies (like VA, DoD, NIH), and research, directly influencing the demand and procurement of medical devices.
This committee directly regulates the FDA, which is the primary approval and oversight body for medical devices. Its decisions on product approvals, safety standards, and labeling directly impact market access and R&D. Labor laws also affect manufacturing costs.
This committee's oversight of intellectual property and antitrust laws is critical for a medical device manufacturer. Patent protection is vital for new products, and antitrust reviews can impact mergers or market practices.
The Department of Veterans Affairs (VA) is a significant purchaser of medical devices. This committee's funding decisions directly impact government healthcare contractors and medical device manufacturers serving veterans.